For these patients and for imatinib-intolerant cases, other PDGFR-targeting drugs, such as sorafenib or midostaurin, should be considered provided that the disease still presents as a chronic PDGFR-dependent neoplasm. The gene discussed is PDGFRB; the disease is neoplasm.